These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25404640)

  • 1. VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells.
    Moore JD; Staniszewska A; Shaw T; D'Alessandro J; Davis B; Surgenor A; Baker L; Matassova N; Murray J; Macias A; Brough P; Wood M; Mahon PC
    Oncotarget; 2014 Dec; 5(24):12862-76. PubMed ID: 25404640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Targeting of the Pyruvate Dehydrogenase Complex/Pyruvate Dehydrogenase Kinase (PDC/PDK) Axis in Cancer.
    Stacpoole PW
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Pyruvate Dehydrogenase Kinase as a Therapeutic Strategy against Cancer.
    Sradhanjali S; Reddy MM
    Curr Top Med Chem; 2018; 18(6):444-453. PubMed ID: 29788890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutrient deprivation induces the Warburg effect through ROS/AMPK-dependent activation of pyruvate dehydrogenase kinase.
    Wu CA; Chao Y; Shiah SG; Lin WW
    Biochim Biophys Acta; 2013 May; 1833(5):1147-56. PubMed ID: 23376776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-guided development of specific pyruvate dehydrogenase kinase inhibitors targeting the ATP-binding pocket.
    Tso SC; Qi X; Gui WJ; Wu CY; Chuang JL; Wernstedt-Asterholm I; Morlock LK; Owens KR; Scherer PE; Williams NS; Tambar UK; Wynn RM; Chuang DT
    J Biol Chem; 2014 Feb; 289(7):4432-43. PubMed ID: 24356970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy.
    Anwar S; Shamsi A; Mohammad T; Islam A; Hassan MI
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188568. PubMed ID: 34023419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase.
    Brough PA; Baker L; Bedford S; Brown K; Chavda S; Chell V; D'Alessandro J; Davies NG; Davis B; Le Strat L; Macias AT; Maddox D; Mahon PC; Massey AJ; Matassova N; McKenna S; Meissner JW; Moore JD; Murray JB; Northfield CJ; Parry C; Parsons R; Roughley SD; Shaw T; Simmonite H; Stokes S; Surgenor A; Stefaniak E; Robertson A; Wang Y; Webb P; Whitehead N; Wood M
    J Med Chem; 2017 Mar; 60(6):2271-2286. PubMed ID: 28199108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific ion influences on self-association of pyruvate dehydrogenase kinase isoform 2 (PDHK2), binding of PDHK2 to the L2 lipoyl domain, and effects of the lipoyl group-binding site inhibitor, Nov3r.
    Hiromasa Y; Yan X; Roche TE
    Biochemistry; 2008 Feb; 47(8):2312-24. PubMed ID: 18220415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diverse mechanisms of inhibition of pyruvate dehydrogenase kinase by structurally distinct inhibitors.
    Mann WR; Dragland CJ; Vinluan CC; Vedananda TR; Bell PA; Aicher TD
    Biochim Biophys Acta; 2000 Jul; 1480(1-2):283-92. PubMed ID: 11004568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells.
    Motawi TM; Sadik NA; Fahim SA; Shouman SA
    Chem Biol Interact; 2015 May; 233():147-56. PubMed ID: 25863232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Dihydroxyphenyl Sulfonylisoindoline Derivatives as Liver-Targeting Pyruvate Dehydrogenase Kinase Inhibitors.
    Tso SC; Lou M; Wu CY; Gui WJ; Chuang JL; Morlock LK; Williams NS; Wynn RM; Qi X; Chuang DT
    J Med Chem; 2017 Feb; 60(3):1142-1150. PubMed ID: 28085286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nematode pyruvate dehydrogenase kinases: role of the C-terminus in binding to the dihydrolipoyl transacetylase core of the pyruvate dehydrogenase complex.
    Chen W; Komuniecki PR; Komuniecki R
    Biochem J; 1999 Apr; 339 ( Pt 1)(Pt 1):103-9. PubMed ID: 10085233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase (PDC/PDK) axis to discover potent PDK inhibitors through structure-based virtual screening and pharmacological evaluation.
    Gan L; Yang Y; Liang Z; Zhang M; He Y; Zhang SL
    Eur J Med Chem; 2024 Jan; 264():116008. PubMed ID: 38056298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells.
    McFate T; Mohyeldin A; Lu H; Thakar J; Henriques J; Halim ND; Wu H; Schell MJ; Tsang TM; Teahan O; Zhou S; Califano JA; Jeoung NH; Harris RA; Verma A
    J Biol Chem; 2008 Aug; 283(33):22700-8. PubMed ID: 18541534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of the mammalian pyruvate dehydrogenase kinases in the prevention of hyperglycaemia.
    Sugden MC; Holness MJ
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Jul; 2(2):151-65. PubMed ID: 12476789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unexpected Discovery of Dichloroacetate Derived Adenosine Triphosphate Competitors Targeting Pyruvate Dehydrogenase Kinase To Inhibit Cancer Proliferation.
    Zhang SL; Hu X; Zhang W; Tam KY
    J Med Chem; 2016 Apr; 59(7):3562-8. PubMed ID: 27006991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenic mechanisms underlying X-linked Charcot-Marie-Tooth neuropathy (CMTX6) in patients with a pyruvate dehydrogenase kinase 3 mutation.
    Perez-Siles G; Ly C; Grant A; Drew AP; Yiu EM; Ryan MM; Chuang DT; Tso SC; Nicholson GA; Kennerson ML
    Neurobiol Dis; 2016 Oct; 94():237-44. PubMed ID: 27388934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ciprofloxacin Therapy Results in Mitigation of ATP Loss after Irradiation Combined with Wound Trauma: Preservation of Pyruvate Dehydrogenase and Inhibition of Pyruvate Dehydrogenase Kinase 1.
    Swift JM; Smith JT; Kiang JG
    Radiat Res; 2015 Jun; 183(6):684-92. PubMed ID: 26010714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyruvate dehydrogenase kinase isoform 2 activity limited and further inhibited by slowing down the rate of dissociation of ADP.
    Bao H; Kasten SA; Yan X; Roche TE
    Biochemistry; 2004 Oct; 43(42):13432-41. PubMed ID: 15491150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.